Fast Five Quiz: Follicular Lymphoma

Emmanuel C. Besa, MD


January 05, 2021

First-line therapy for follicular lymphoma typically consists of combination therapy that includes rituximab. A typical regimen is rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP). Others include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); CHOP followed by tositumomab/iodine-131 radioimmunotherapy (CHOP-RIT); and bendamustine plus rituximab.

Advanced disease without systemic symptoms, cytopenias, or bulky disease can often be managed with observation until organ function is jeopardized.

Single agents are used only in selected patients because they are less effective than combination therapy. Clinicians may opt for them in situations where palliation is the treatment goal. Options include chlorambucil, rituximab, and idelalisib, among others.

At least for localized disease — seen in only 10% of patients at presentation — radiation therapy can be curative in about half of cases.

Learn more about the management of follicular lymphoma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: